The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).
Vassiliki Papadimitrakopoulou
Research Funding - Bayer/Onyx; Merck
Ignacio Ivan Wistuba
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Anne S. Tsao
No relevant relationships to disclose
Neda Kalhor
No relevant relationships to disclose
Frank V. Fossella
No relevant relationships to disclose
John Heymach
No relevant relationships to disclose
Christine M Alden
No relevant relationships to disclose
Scott N. Gettinger
No relevant relationships to disclose
Kevin R. Coombes
No relevant relationships to disclose
Pierre Saintigny
No relevant relationships to disclose
Ximing Tang
No relevant relationships to disclose
Emily Duffield
No relevant relationships to disclose
Julie Boyer
No relevant relationships to disclose
Suzanne E Davis
No relevant relationships to disclose
Garth Powis
No relevant relationships to disclose
David J. Mauro
No relevant relationships to disclose
Eric H. Rubin
No relevant relationships to disclose
Waun Ki Hong
No relevant relationships to disclose
Roy S. Herbst
No relevant relationships to disclose